老字号健康产品“鱼龙混杂”，谁从“同仁堂”假磷虾油中受益？

Core Viewpoint - The controversy surrounding the alleged fraud involving krill oil products linked to Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. continues to unfold, with the parent company, Beijing Tongrentang Co., Ltd., distancing itself from the issue, despite being associated with the implicated company [1][2]. Group 1: Company Relations and Responsibilities - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. is not a subsidiary of Beijing Tongrentang Co., Ltd. but is an affiliated company, raising concerns about brand reputation and accountability [1]. - Legal experts suggest that the relationship between the two companies indicates a shared responsibility for maintaining the brand's commercial reputation, despite the parent company's claims of ignorance regarding the fraud [2][3]. Group 2: Consumer Protection and Market Practices - The Shanghai Consumer Protection Committee has raised concerns about the suspiciously low procurement price of the krill oil products, which is significantly lower than the retail price, suggesting potential fraud involving the substitution of krill oil with fish oil extracts [2]. - The committee emphasizes the need for regulatory bodies to address consumer concerns and eliminate deceptive practices in the health product market, highlighting a broader issue of quality inconsistency among products from established brands [2]. - Legal experts assert that if the sales of the fraudulent products were led by Sichuan Tongrentang, the company and its sales channels should be held accountable for the incident [3].